That'll be great timing for the rebate cash. R&D spend for next two quarters could well be less than Q1 & Q2 given majority of 201 patients must be past the 12 month mark. They may even be able to spend more on marketing or new hires.
Presentation is quite science focussed which is good for some but not all - downplays the huge growth opportunity coming up in Jan especially considering chance of accelerated approval in this unmet need area.
Hopefully after the Aug 31 2bn options expire, coupled with exposure at conferences, maybe more data from 202 study too, SP starts to gain momentum before 201 read-out. lets see. cheers.
That'll be great timing for the rebate cash. R&D spend for next...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $4.579K | 1.526M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 749591 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 133062022 | 26 |
View Market Depth
| Last trade - 14.03pm 13/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |